These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 26478546)

  • 1. When do patients prefer a direct oral anticoagulant over a vitamin K antagonist?
    Boom MS; Berghuis EM; Nieuwkerk PT; Pinedo S; Büller HR
    Neth J Med; 2015 Oct; 73(8):368-72. PubMed ID: 26478546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preference for direct oral anticoagulants in patients treated with vitamin K antagonists for venous thromboembolism.
    Brekelmans MP; Kappelhof M; Nieuwkerk PT; Nierman M; Buller HR; Coppens M
    Neth J Med; 2017 Mar; 75(2):50-55. PubMed ID: 28276323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Factors Associated with Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients with Non-valvular Atrial Fibrillation].
    Saliba L; Mondoly P; Duparc A; Bura-Rivière A; Maury P; Calmels V; Sallerin B; Pathak A; Montastruc JL; Bagheri H
    Therapie; 2015; 70(6):485-92. PubMed ID: 26223162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct oral anticoagulants: to switch or not to switch?
    Lugthart S; Leebeek FW
    Neth J Med; 2015 Oct; 73(8):359-61. PubMed ID: 26478544
    [No Abstract]   [Full Text] [Related]  

  • 5. Development of a tool to identify patients' preference for vitamin K antagonist or direct oral anticoagulant therapy.
    Zolfaghari S; Harenberg J; Froelich L; Wehling M; Weiss C
    Semin Thromb Hemost; 2014 Feb; 40(1):121-8. PubMed ID: 24381153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recanalization therapies in acute ischemic stroke patients: impact of prior treatment with novel oral anticoagulants on bleeding complications and outcome.
    Seiffge DJ; Hooff RJ; Nolte CH; Béjot Y; Turc G; Ikenberg B; Berge E; Persike M; Dequatre-Ponchelle N; Strbian D; Pfeilschifter W; Zini A; Tveiten A; Næss H; Michel P; Sztajzel R; Luft A; Gensicke H; Traenka C; Hert L; Scheitz JF; De Marchis GM; Bonati LH; Peters N; Charidimou A; Werring DJ; Palm F; Reinhard M; Niesen WD; Nagao T; Pezzini A; Caso V; Nederkoorn PJ; Kägi G; von Hessling A; Padjen V; Cordonnier C; Erdur H; Lyrer PA; Brouns R; Steiner T; Tatlisumak T; Engelter ST;
    Circulation; 2015 Sep; 132(13):1261-9. PubMed ID: 26232277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential cellular effects of old and new oral anticoagulants: consequences to the genesis and progression of atherosclerosis.
    Schurgers LJ; Spronk HM
    Thromb Haemost; 2014 Nov; 112(5):909-17. PubMed ID: 25298033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching frail older people with AF from a vitamin K antagonist to a DOAC.
    Drug Ther Bull; 2024 Jul; 62(8):115. PubMed ID: 38839266
    [No Abstract]   [Full Text] [Related]  

  • 9. [Quality of life of elderly people on oral anticoagulant for atrial fibrillation: VKA versus direct oral anticoagulants].
    Fareau S; Baumstarck K; Farcet A; Molines C; Auquier P; Retornaz F
    Geriatr Psychol Neuropsychiatr Vieil; 2015 Mar; 13(1):45-54. PubMed ID: 25786423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis of risk of stroke and thrombo-embolism with rivaroxaban versus vitamin K antagonists in ablation and cardioversion of atrial fibrillation.
    Nairooz R; Sardar P; Pino M; Aronow WS; Sewani A; Mukherjee D; Paydak H; Maskoun W
    Int J Cardiol; 2015; 187():345-53. PubMed ID: 25839640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-vitamin K antagonist oral anticoagulants for the treatment of intracardiac thrombosis.
    Ghaffarpasand E; Tehrani MD; Marszalek J; Chi G
    J Thromb Thrombolysis; 2018 Oct; 46(3):332-338. PubMed ID: 29876713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent changes in practice guidelines for atrial fibrillation management.
    Charneski L; Hollands JM
    Pharmacotherapy; 2014 Nov; 34(11):1118-20. PubMed ID: 25284056
    [No Abstract]   [Full Text] [Related]  

  • 13. Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials.
    Vanassche T; Hirsh J; Eikelboom JW; Ginsberg JS
    Thromb Haemost; 2014 Nov; 112(5):918-23. PubMed ID: 25187203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prothrombotic risk of vitamin K antagonists during the first days of treatment: One more reason to use new oral anticoagulants.
    Gaertner S; Cordeanu EM; Mirea C; Stephan D
    Int J Cardiol; 2015; 186():141-2. PubMed ID: 25818758
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial.
    ; Bousser MG; Bouthier J; Büller HR; Cohen AT; Crijns H; Davidson BL; Halperin J; Hankey G; Levy S; Pengo V; Prandoni P; Prins MH; Tomkowski W; Torp-Pedersen C; Wyse DG
    Lancet; 2008 Jan; 371(9609):315-21. PubMed ID: 18294998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.
    Senoo K; Lip GY
    Semin Thromb Hemost; 2015 Mar; 41(2):146-53. PubMed ID: 25682085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.
    Mahaffey KW; Wojdyla D; Hankey GJ; White HD; Nessel CC; Piccini JP; Patel MR; Berkowitz SD; Becker RC; Halperin JL; Singer DE; Califf RM; Fox KA; Breithardt G; Hacke W
    Ann Intern Med; 2013 Jun; 158(12):861-8. PubMed ID: 23778903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Frequency of use of oral vitamin K antagonists in patients with atrial fibrillation and cognitive function disturbances].
    Gorzelak P; Zyzak S; Krewko Ł; Mozdzan M; Broncel M
    Pol Merkur Lekarski; 2014 May; 36(215):302-6. PubMed ID: 24964505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimizing the risk of hemorrhagic stroke during anticoagulant therapy for atrial fibrillation.
    Zoppellaro G; Granziera S; Padayattil Jose S; Denas G; Bracco A; Iliceto S; Pengo V
    Expert Opin Drug Saf; 2015 May; 14(5):683-95. PubMed ID: 25803739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of life after switching from well-controlled vitamin K antagonist to direct oral anticoagulant: Little to GAInN.
    van Miert JHA; Kooistra HAM; Veeger NJGM; Westerterp A; Piersma-Wichers M; Meijer K
    Thromb Res; 2020 Jun; 190():69-75. PubMed ID: 32315869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.